InSilicoTrials' AI platform hyper-accelerates drug development
Corinna Herrmann
Can AI revolutionize pharmaceutical research? InSilicoTrials leverages in silico simulations and AI to make drug development faster, safer, and more cost-effective. CEO Luca Emili explains how the platform works, the problems it solves, and its impact on the pharmaceutical industry.

How would you explain your solution in three sentences to a professional colleague from the health sector?
InSilicoTrials offers a cloud simulation platform using AI and in silico techniques to predict clinical trial outcomes, reducing the need for extensive trials and accelerating R&D. As a premier problem solver in drug development, our platform supports diverse disease areas with cutting-edge models, privacy-preserving synthetic patient simulations, and virtual patients. We provide digital evidence to enhance funding prospects while significantly cutting R&D time and costs.

What problem motivated you to start the company?
Founded in 2018, InSilicoTrials emerged to address critical challenges in drug development, driven by a profound concern for patient well-being. Our team of life science, cybersecurity, and digital innovation experts aim to revolutionize healthcare through a cutting-edge digital simulation platform. The industry struggles with lengthy, costly, and high-failure-rate drug development, often taking $2.6 billion and 12 years to bring new medicines to market. Clinical trials are essential but time-consuming, expensive, and risky for patients. Our platform tackles these inefficiencies and risks, making drug development faster, safer, and more cost-effective, ultimately enhancing patient care.

How do you convince a pharmaceutical company, a health insurance company or another potential client to set up a pilot project with you?
To convince pharmaceutical or other potential clients to collaborate with us, we emphasize our unique value and proven benefits. Our platform combines state-of-the-art AI, advanced simulation tools & real-world patient data, reducing the time and cost of traditional clinical trials. Unlike other solutions, we offer an end-to-end platform for all stages of drug development.
Our differentiator is having models provided by academics, researchers, and regulators, covering many therapeutic areas for pre-clinical and clinical trials.
Our cloud-based platform integrates seamlessly into existing workflows, minimizing disruption and maximizing efficiency. We showcase case studies and data from previous projects, demonstrating reduced trial times, cost savings, and improved safety profiles. This builds trust and highlights our platform's reliability and effectiveness.
Our team provides continuous support and customization, ensuring our solution meets each client's specific needs.
Who are your current customer (groups) and who do you want your potential customers to be?
Our current customers include biotech, pharmaceutical companies, and contract research organizations (CROs). We cater to researchers & companies that simulate nonclinical and clinical trials using our digital simulation library, similar to how users access music on Spotify or Apple Music. We provide easy access to powerful tools & use value-based pricing to sell our services.
We are active in European markets, the US, and Asia and we aim to further expand our presence in the US, Switzerland & Germany. Our goal is to achieve critical mass in oncology, neurodegenerative diseases, and patient-specific treatments while enhancing our clients' database.
Where do you see yourself in 3 years and how can 5-HT support you?
In three years, InSilicoTrials will be part of a paradigm shift in the pharmaceutical industry, pushing for silico technologies to become standard practice for drug development. We will continue our work to streamline R&D, reduce costs, and improve drug safety and efficacy across the life sciences industry by leveraging computational models and AI.
5-HT can support by connecting us with potential business partners & investors & access to their network & resources.
Related posts
You may be interested in these articles:
5-HT Chemistry & Health Newsletter
Want the latest tech and industry news, events, relevant info from the ecosystem and more?
Subscribe to 5-HT Newsletter now Subscribe to 5-HT Newsletter now
Become part of the 5-HT Chemistry & Health
Exchange ideas with innovative startups and future-oriented companies in our ecosystem. We look forward to meeting you!